The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Will Be The Estimated Market Valuation Of The Tardive Dyskinesia Treatment Market By The End Of 2030?
The tardive dyskinesia treatment market size has seen significant expansion in recent years. This market is forecast to increase from $2.61 billion in 2025 to $2.84 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 8.8%. The historical growth of this market stems from elements such as the prolonged consumption of antipsychotic medications, a rise in awareness regarding tardive dyskinesia, the limited availability of specific treatment alternatives, the growing occurrence of mental health disorders, and the development of hospital neurology departments.
The tardive dyskinesia treatment market is projected to experience substantial growth over the coming years. This market is anticipated to reach $3.9 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.3%. This projected growth during the forecast period can be primarily attributed to several factors, including the introduction of new dopamine-depleting therapies, wider acceptance of deep brain stimulation, broader uses of botulinum toxin, the incorporation of telemedicine for managing movement disorders, and increased funding for individualized rehabilitation and cognitive therapies. Key trends expected during the forecast period involve the growing uptake of dopamine-depleting agents and anticholinergic drugs, a heightened demand for botulinum toxin injections specifically for focal dyskinesia, an expansion in the application of deep brain stimulation for treatment-resistant tardive dyskinesia, the development of personalized injection strategies and multi-target DBS techniques, and the incorporation of cognitive behavioral therapy alongside supportive rehabilitation initiatives.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=27431&type=smp
What Major Growth Drivers Are Shaping The Outlook Of The Tardive Dyskinesia Treatment Market?
The growing incidence of psychiatric disorders is expected to drive the expansion of the tardive dyskinesia treatment market. Psychiatric disorders cover a broad spectrum of mental health conditions that affect an individual’s mood, thought processes, behavior, and overall daily functioning, often requiring professional diagnosis and therapy. The prevalence of these disorders is increasing due to heightened stress and lifestyle pressures, which include heavy workloads, social isolation, and insufficient time for personal well-being. Tardive dyskinesia treatment plays a crucial role in managing involuntary movement symptoms, thereby improving overall treatment effectiveness and enhancing the quality of life for those with psychiatric disorders who depend on long-term antipsychotic medication. As an illustration, in November 2023, data from NHS England, a UK government health agency, indicated that around 20.3 % of children aged 8 to 16, 23.3 % of individuals aged 17 to 19, and 21.7 % of those aged 20 to 25 had a probable mental disorder in 2023. Consequently, the rising prevalence of psychiatric disorders is a key factor propelling the growth of the tardive dyskinesia treatment market.
Which Segment Classifications Shape The Tardive Dyskinesia Treatment Market?
The tardive dyskinesia treatment market covered in this report is segmented –
1) By Treatment Type: Medications, Botulinum Toxin Injections, Deep Brain Stimulation, Other Treatment Types
2) By Drug: Valbenazine, Amantadine, Tetrabenazine, Clonazepam, Other Drugs
3) By Route Of Administration: Oral Administration, Injection, Transdermal Patches
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels
5) By End-Users: Hospitals, Specialty Clinics, Other End-Users
Subsegments:
1) By Medications: Antipsychotic Medications, Benzodiazepines, Dopamine-Depleting Agents, Anticholinergic Agents
2) By Botulinum Toxin Injections: Facial Muscle Injections, Neck Muscle Injections, Limb Muscle Injections, Customized Injection Protocols
3) By Deep Brain Stimulation: Subthalamic Nucleus Stimulation, Globus Pallidus Interna Stimulation, Thalamic Stimulation, Multi-Target Stimulation
4) By Other Treatment Types: Supportive Therapies, Cognitive Behavioral Therapy, Physical Rehabilitation, Emerging Experimental Treatments
How Are Trends Impacting The Tardive Dyskinesia Treatment Market?
Leading companies operating within the tardive dyskinesia treatment market are concentrating on developing innovative medications, such as sprinkle capsule formulations, to enhance medication adherence for patients facing swallowing challenges. These sprinkle capsule formulations are designed to be opened and dispersed onto soft food, making them easier for individuals with dysphagia or difficulty consuming whole capsules to swallow. For example, in July 2024, Neurocrine Biosciences Inc., a US-based biotechnology company, introduced Ingrezza sprinkle (valbenazine) capsules, which stands as the leading prescribed vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of adults with tardive dyskinesia and chorea linked to Huntington’s disease. This VMAT2 inhibitor functions by regulating dopamine levels in the brain to aid in managing involuntary movements. The drug is offered as a once-daily oral capsule, including a sprinkle formulation specifically developed to simplify administration for patients who experience difficulty swallowing.
Which Companies Are Expanding Their Footprint In The Tardive Dyskinesia Treatment Market?
Major companies operating in the tardive dyskinesia treatment market are AbbVie Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Limited, Otsuka Pharmaceutical Co. Ltd., Jazz Pharmaceuticals plc, Kyowa Kirin Co Ltd., H. Lundbeck A/S, Neurocrine Biosciences Inc., Acadia Pharmaceuticals Inc., Upsher-Smith Laboratories LLC, Adamas Pharmaceuticals Inc., Sunovion Pharmaceuticals Inc., Mitsubishi Tanabe Pharma Corporation.
Read the full tardive dyskinesia treatment market report here:
https://www.thebusinessresearchcompany.com/report/tardive-dyskinesia-treatment-global-market-report
Which Regions Are Projected To Dominate The Tardive Dyskinesia Treatment Market In The Coming Years?
North America was the largest region in the tardive dyskinesia treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tardive dyskinesia treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Tardive Dyskinesia Treatment Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=27431&type=smp
Browse Through More Reports Similar to the Global Tardive Dyskinesia Treatment Market 2026, By The Business Research Company
Tax Preparation Services Market Report 2026
https://www.thebusinessresearchcompany.com/report/tax-preparation-services-global-market-report
Tax Management Software Market Report 2026
https://www.thebusinessresearchcompany.com/report/tax-management-software-global-market-report
Tax Management Market Report 2026
https://www.thebusinessresearchcompany.com/report/tax-management-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model